Cargando…

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients

Purpose. To compare the efficacy of intravitreal bevacizumab versus ranibizumab in the treatment of neovascular age-related macular degeneration (nAMD). Methods. Retrospective, comparative study. The newly diagnosed nAMD patients who were treated with intravitreal bevacizumab or ranibizumab on an as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozkaya, Abdullah, Alkin, Zeynep, Karakucuk, Yalcin, Yasa, Dilek, Yazici, Ahmet Taylan, Demirok, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914220/ https://www.ncbi.nlm.nih.gov/pubmed/24558597 http://dx.doi.org/10.1155/2013/151027

Ejemplares similares

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
por: Alkin, Zeynep, et al.
Publicado: (2013)

Long Term Result of Intravitreal Bevacizumab in a Patient Newly Transformed to Proliferative Macular Telangiectasia Type 2
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to morning glory syndrome in a child
por: Özkaya, Abdullah, et al.
Publicado: (2016)

Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results
por: Ozkaya, Abdullah, et al.
Publicado: (2015)

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

Detailed Ophthalmologic Evaluation of Posterior Microphthalmos
por: Alkin, Zeynep, et al.
Publicado: (2014)

Diurnal Choroidal Thickness Changes in Normal Eyes of Turkish People Measured by Spectral Domain Optical Coherence Tomography
por: Osmanbasoglu, Ozen Ayrancı, et al.
Publicado: (2013)

Comparison between Intravitreal Triamcinolone with Grid Laser Photocoagulation versus Bevacizumab with Grid Laser Photocoagulation Combinations for Branch Retinal Vein Occlusion
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Anti-Vascular Endothelial Growth Factor Treatment for Proliferative Macular Telangiectasia Type 2
por: Alkin, Zeynep, et al.
Publicado: (2016)

Efficacy of Selective Laser Trabeculoplasty in Medically Uncontrolled Glaucoma
por: Sayin, Nihat, et al.
Publicado: (2013)

Selective Laser Trabeculoplasty for Glaucoma Secondary to Emulsified Silicone Oil after Pars Plana Vitrectomy: A Pilot Study
por: Alkin, Zeynep, et al.
Publicado: (2014)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
por: Biswas, Partha, et al.
Publicado: (2011)

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
por: Kodjikian, Laurent, et al.
Publicado: (2014)

Evaluation of Macular Microcirculation in Healthy Children Using Optical Coherence Tomography Angiography
por: Karakucuk, Yalcin, et al.
Publicado: (2021)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Steroid-induced central serous chorioretinopathy in a patient with non-arteritic anterior ischemic optic neuropathy
por: Alkin, Zeynep, et al.
Publicado: (2015)

Focal Laser Photocoagulation in Non-Center Involved Diabetic Macular Edema
por: Perente, Irfan, et al.
Publicado: (2014)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
por: Wang, Zongyi, et al.
Publicado: (2020)

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
por: Mantel, Irmela, et al.
Publicado: (2014)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
por: Maunz, Andreas, et al.
Publicado: (2023)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Topical Nepafenac in Treatment of Acute Central Serous Chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2013)

Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen
por: Menke, Marcel N, et al.
Publicado: (2014)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_to389dflscv9vn3d50f3bmi4fp